Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SSKN
stocks logo

SSKN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
8.49M
-11.54%
-0.330
-72.03%
7.33M
+7.58%
-0.415
-28.45%
8.07M
+5.31%
-0.395
-34.17%
Estimates Revision
The market is revising Upward the revenue expectations for STRATA Skin Sciences, Inc. (SSKN) for FY2025, with the revenue forecasts being adjusted by 2.35% over the past three months. During the same period, the stock price has changed by -17.98%.
Revenue Estimates for FY2025
Revise Upward
up Image
+2.35%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-2.88%
In Past 3 Month
Stock Price
Go Down
down Image
-17.98%
In Past 3 Month
Wall Street analysts forecast SSKN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SSKN is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast SSKN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SSKN is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.460
sliders
Low
4.00
Averages
4.00
High
4.00
Current: 1.460
sliders
Low
4.00
Averages
4.00
High
4.00
Maxim Group
Anthony Vendetti
Strong Buy
Initiates
$6
2025-02-27
Reason
Maxim Group
Anthony Vendetti
Price Target
$6
2025-02-27
Initiates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Strata Skin Sciences Inc (SSKN.O) is -0.97, compared to its 5-year average forward P/E of -6.71. For a more detailed relative valuation and DCF analysis to assess Strata Skin Sciences Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.71
Current PE
-0.97
Overvalued PE
-1.17
Undervalued PE
-12.24

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.35
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
33.73
Undervalued EV/EBITDA
-34.42

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.89
Current PS
0.00
Overvalued PS
1.45
Undervalued PS
0.32
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

SSKN News & Events

Events Timeline

(ET)
2025-10-28
08:18:26
Strata Skin Sciences Receives COFEPRIS Approval for TheraClear in Mexico
select
2025-10-20 (ET)
2025-10-20
08:21:34
Strata Skin Sciences Offers Update on Legal Matters and Strategic Positioning
select
2025-10-14 (ET)
2025-10-14
08:29:21
Strata Skin Sciences Reveals Clinical Case Study on 308-nm Excimer Laser
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
10-29Benzinga
Teradyne Shares Surge Over 20%; Check Out 20 Stocks Making Moves in Premarket Trading

  • Teradyne's Strong Performance: Teradyne Inc. shares surged 20.7% in pre-market trading after reporting third-quarter earnings of 85 cents per share, exceeding analyst expectations of 79 cents, along with sales of $769.210 million, surpassing the $743.776 million estimate.

  • Notable Gainers: Several stocks saw significant pre-market gains, including Profusa Inc. (+72.8%), Founder Group Ltd (+59.4%), and Vsee Health Inc. (+44.3%), driven by positive developments such as manufacturing capacity increases and regulatory approvals.

  • Major Losers: Stride Inc. experienced a sharp decline of 36.4% after providing disappointing sales guidance, while Varonis Systems Inc. and Akebia Therapeutics Inc. also fell significantly due to lower-than-expected revenue and trial design issues, respectively.

  • Market Overview: The pre-market trading session showed a mix of gains and losses across various stocks, with notable movements in both directions, reflecting investor reactions to earnings reports and company announcements.

[object Object]
Preview
9.0
10-29Benzinga
STRATA Skin Sciences Sees 25% Pre-Market Increase — Find Out the Reasons

  • Stock Performance: STRATA Skin Sciences Inc. (SSKN) saw a 24.87% increase in premarket trading to $2.41 after receiving Mexican regulatory approval for its TheraClearX acne treatment system, following a previous 14.88% rise to $1.93 in regular trading.

  • Regulatory Approval: The Mexican health regulator COFEPRIS granted Device Registration No. 3187E2024SSA for TheraClearX, allowing it to be marketed and used in clinical settings across Mexico until November 2029.

  • Commercial Rollout: STRATA has initiated a commercial rollout of TheraClearX in partnership with MINO Labs, enabling physicians to use the system under a usage-based model without upfront costs.

  • Market Opportunity: The professional acne medication segment in Mexico is expected to nearly double by 2030, with a projected CAGR of 10.2%, highlighting significant growth potential for STRATA in the dermatology market.

[object Object]
Preview
9.0
10-03Newsfilter
Eczema Awareness Month: Clinical Research Confirms Strata Skin Sciences' XTRAC® Excimer Laser as a Revolutionary Treatment for Localized Atopic Dermatitis

  • Eczema Awareness Month: STRATA Skin Sciences highlights the effectiveness of the XTRAC® Excimer Laser for treating localized atopic dermatitis, as the American Medical Association expands its indications, allowing for broader reimbursement options.

  • Clinical Evidence and Impact: Numerous studies demonstrate the excimer laser's safety and efficacy, showing significant improvements in patients with atopic dermatitis, including reduced symptoms and long-lasting remission, particularly in difficult-to-treat areas like hands and feet.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Strata Skin Sciences Inc (SSKN) stock price today?

The current price of SSKN is 1.46 USD — it has increased 3.55 % in the last trading day.

arrow icon

What is Strata Skin Sciences Inc (SSKN)'s business?

STRATA Skin Sciences, Inc. is a medical technology company in dermatology. The Company is engaged in developing, commercializing and marketing products for the treatment of dermatologic conditions. The Company operates through two segments: Dermatology Recurring Procedures and Dermatology Procedures Equipment. The Company’s products include the XTRAC and Pharos excimer lasers and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. Its products also include the TheraClear Acne Therapy System utilized in the treatment of mild to moderate inflammatory, comedonal and pustular acne. The XTRAC and Pharos excimer laser technology emits highly concentrated ultraviolet (UV) light targeted primarily towards autoimmune dermatological skin disorders, such as psoriasis, vitiligo, atopic dermatitis, and eczema, among others. VTRAC is a UV light lamp system that works in much the same way as the XTRAC.

arrow icon

What is the price predicton of SSKN Stock?

Wall Street analysts forecast SSKN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SSKN is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Strata Skin Sciences Inc (SSKN)'s revenue for the last quarter?

Strata Skin Sciences Inc revenue for the last quarter amounts to 6.93M USD, decreased -21.23 % YoY.

arrow icon

What is Strata Skin Sciences Inc (SSKN)'s earnings per share (EPS) for the last quarter?

Strata Skin Sciences Inc. EPS for the last quarter amounts to -0.36 USD, decreased -29.41 % YoY.

arrow icon

What changes have occurred in the market's expectations for Strata Skin Sciences Inc (SSKN)'s fundamentals?

The market is revising Upward the revenue expectations for STRATA Skin Sciences, Inc. (SSKN) for FY2025, with the revenue forecasts being adjusted by 2.35% over the past three months. During the same period, the stock price has changed by -17.98%.
arrow icon

How many employees does Strata Skin Sciences Inc (SSKN). have?

Strata Skin Sciences Inc (SSKN) has 106 emplpoyees as of December 05 2025.

arrow icon

What is Strata Skin Sciences Inc (SSKN) market cap?

Today SSKN has the market capitalization of 8.60M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free